Kojin Therapeutics

Kojin is utilizing revolutionary advancements in cell state and ferroptosis biology to develop innovative treatments and remedies for traditionally challenging diseases. By establishing connections between intricate cell conditions and established biochemical processes, Kojin has pioneered an exclusive strategy for ferroptosis-based drug exploration, enabling the creation of targeted therapies for a wide spectrum of disabling diseases. The company was founded by prominent scientists Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan. Kovina Therapeutics, a preclinical stage biotechnology company, focuses on creating pioneering antiviral therapeutics tailored to address cancers and precancerous infections caused by Human Papillomavirus (HPV). Committed to offering novel treatment options to patients infected with HPV, the company's development efforts aim to provide hope for non-surgical treatments. Soin Therapeutics is a pharmaceutical company dedicated to developing new medications for rare, orphan diseases. Their primary product is an innovative formulation of naltrexone designed for patients with complex regional pain syndrome (CRPS), which has received orphan drug status from the FDA. CRPS is a painful and incapacitating disease, and Soin Therapeutics believes they have discovered a solution that can significantly benefit many individuals who are suffering.